Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.
A non-profit genomics research institute.
James Lewis Abbruzzese is the Chief of the Duke Division of Medical Oncology and associate director for Clinical Research for the Duke Cancer Institute. Previously, Abbruzzese was Chairman of the Department of Gastrointestinal Medical Oncology at the University of Texas M. D. Anderson Cancer Center where he held the M. G. and Lillie A. Johnson Chair for Cancer Treatment and Research and the Annie Laurie Howard Research Distinguished Professorship. Abbruzzese is one of the world's leaders in the clinical study and treatment of pancreatic cancer.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
Olufunmilayo I. Olopade born in the year 1957, is a Nigerian hematology oncologist, Associate Dean for Global Health and Walter L. Palmer, Distinguished Service Professor in Medicine and Human Genetics at the University of Chicago. She also serves as director of the University of Chicago Hospital's Cancer Risk Clinic.
Naoto T Ueno is a Professor of Medicine at The University of Texas MD Anderson Cancer Center; his research is in the area of inflammatory breast cancer and the molecular mechanism of metastasis and tumorigenicity. Ueno is also affiliated with the Keio University as a visiting professor.
William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
Carlos L. Arteaga is the Associate Director for Clinical Research, director of the Center for Cancer Targeted Therapies, and professor of Cancer Biology and Medicine at Vanderbilt-Ingram Cancer Center. In 2014–2015, he was the president of the American Association for Cancer Research.
Scott M. Lippman is the former Director of Moores Cancer Center at the University of California, San Diego and current Professor of Medicine at UC San Diego School of Medicine.
Bruce Allan Chabner is an American medical researcher who worked at the National Cancer Institute and now is a professor of medicine at Harvard Medical School. He is also the director of clinical research at the Cancer Center at Massachusetts General Hospital. His research focuses on anti-folate drugs for the treatment of cancer. His work at NIH led to the development of Taxol, a commonly prescribed breast cancer drug.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Steven T. Rosen is the Provost and chief scientific officer of the City of Hope National Medical Center in Duarte, California. In addition to directing City of Hope's Comprehensive Cancer Center, Rosen leads the Beckman Research Institute at City of Hope, and the Irell & Manella Graduate School of Biological Sciences. Previously (1989-2014) Rosen was the director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, which was awarded comprehensive cancer center status by the National Cancer Institute (NCI) in 1997.
Joseph Rocco Bertino was an American researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research focused on the treatment of lymphoma.
Robert Maki is an American medical oncologist, Professor of Medicine at the Hospital of the University of Pennsylvania, He is a specialist in the management of and translational research regarding sarcoma, the group of connective tissue malignancies that include leiomyosarcoma, gastrointestinal stromal tumor (GIST), liposarcoma, angiosarcoma, Ewing sarcoma, desmoid tumor and many others.
Luis Alberto Diaz, Jr. is the Head of the Division of Solid Tumor Oncology in Memorial Sloan Kettering’s Department of Medicine.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.
James R. Downing is an American clinical executive. He is the president and chief executive officer of St. Jude Children's Research Hospital.
Stephanie Lynn Schutt Graff is an American breast medical oncologist. She is the Director of Breast Oncology at the Lifespan Cancer Institute and an Assistant Professor of Medicine at Alpert Medical School. Previously she was the Director of both the Breast Program and Clinical Research at Sarah Cannon Research Institute at HCA Midwest Health at Sarah Cannon Research Institute and Associate Director of the Breast Cancer Research Program at Sarah Cannon Research Institute.
Chi Van Dang is a hematological oncologist and researcher, currently serving as the Scientific Director of Ludwig Institute for Cancer Research. He is known for his research on genetics, the MYC gene and the cellular energy metabolism of cancer.
Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.
